-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Srixon Announces Buy 2, Get 1 Free Golf Ball Promotion
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
-
Who Is the Best Spanish-Speaking Private Investigator in Sacramento?
-
Healixa Turns Patents Into Products: FrostPulse(TM) Delivered and Five Eternal Spring(TM) Units Enter Production
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders' Equity Up 21% Since Year-End
-
Nearly Half of Transformation Initiatives Face a 'Momentum Gap' That Puts Value at Risk, NSP & Company Study Finds
-
CXAI Expands Agentic AI Reach into Mid-Market Through EngineRoom's Simpro Partnership
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Agency Guacamole's 10th B.L.N.D. Event Brought Industry Leaders Together for a Conversation on the Evolution of Diversity and Inclusion in Beauty
-
From Pilot to Production: InHand Networks' Practical Approach to Industrial Edge AI
WHO pleads for more support to tackle Ebola outbreak
The World Health Organization called Tuesday for more support across to board to combat the Ebola outbreak raging in the Democratic Republic of Congo, which is still outpacing response efforts.
The outbreak is the biggest ever to have hit the DR Congo, despite being declared less than three months ago.
"The outbreak is unfortunately still expanding beyond the capacity of the response," WHO spokesman Tarik Jasarevic told reporters in Geneva.
"We need more support in terms of finances, but also other resources to scale up all areas of response: treatment capacity, field investigation teams, safe burial teams and community workers."
There have been 3,802 confirmed cases of Ebola in the DRC, including 1,707 deaths. A total of 727 patients have recovered, and there are 275 suspected cases under investigation.
A total of 17,000 contacts of cases are being monitored, with more than 80 percent of them receiving daily check-ups.
Though cases have been reported from five provinces, nearly 90 percent are in the northeastern Ituri province, with nearly all the rest in neighbouring North Kivu.
Jasarevic said the response needed to focus on where the virus is spreading now, and where it might go next.
A viral haemorrhagic fever, Ebola spreads through close contact and infected bodily fluids.
The DRC's 17th Ebola outbreak was declared on May 15 after several deaths in Ituri.
The outbreak is driven by the Bundibugyo species of Ebola -- for which there are no proven safe and efficacious treatments for patients, vaccines, or prophylaxis options to stop people exposed to the virus from falling ill.
But various trials are under way of potential therapies, vaccines and post-exposure antiviral drugs.
Vasee Moorthy, who leads the WHO's research and development blueprint arm, said the early indications were promising.
- Vaccine trials -
Moorthy said new data was emerging on whether the Ervebo vaccine, which works against the Zaire species of Ebola, also provided cross-protection against Bundibugyo in animals.
A WHO vaccine advisory group reviewed the data on Friday and will issue recommendations later this week.
The two front-running candidate vaccines are one using the ChAdOx1 platform, being developed by the University of Oxford and the Serum Institute of India, and another being worked on by US pharma firm Moderna using mRNA technology.
The ChAdOx1 jab started a Phase I trial in Britain on July 24, while the Moderna candidate vaccine is set to start Phase I trials in Canada this week, Moorthy said.
They are being tested on ferrets and on monkeys, while at the same time volunteers in Oxford and Canada are being given different doses of the potential vaccine to assess the immune response as well as safety.
Depending on the results, developers will pick the best dose level to take forward to full-scale Phase III human trials.
Two potential treatments are being tested on confirmed Ebola patients in Ituri: the monoclonal antibody MBP134 and the antiviral drug remdesivir, alone and in combination.
Meanwhile a trial is also taking place of the antiviral drug obeldesivir, for people exposed to confirmed Bundibugyo cases.
The trial in Ituri has enrolled more than 25 high-risk contacts "to evaluate whether this oral medicine, given for 10 days, can prevent onset of disease", said Moorthy.
J.Gomez--AT